WALTHAM, Mass. , Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni , M.D., president and chief executive

- Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track to file INDs for its two lead programs WALTHAM, Mass. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:

WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 1, 2019-- Morphic Holding, Inc. (“ Morphic ”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a price to

WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 26, 2019-- Morphic Holding, Inc. (“ Morphic ”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a

WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of

Deal extends reach of Morphic discovery across all known human integrins Therapeutic potential of Morphic pipeline expanded by inclusion of both   integrin inhibitor and activator   research Collaboration facilitated by Johnson & Johnson Innovation, Boston WALTHAM, Mass.